Adrenomedullin is a recently discovered vasodilating and natriuretic peptide whose physiological and pathophysiological roles remain to be established. Like atrial natiuretic peptide adrenomedullin is expressed in the left ventricle. Ventricular expression of atrial natriuretic peptide is known to be markedly increased by volume or pressure overload. In this study we investigated whether ventricular expression of adrenomedullin is similarly stimulated under such conditions. 2. Ventricular adrenomedullin and atrial natriuretic peptide mRNA levels as well as those of a loading control mRNA (glyceraldehyde-3-phosphate dehydrogenase) were quantified by Northern blot analysis in (a) rats with severe post-infarction heart failure induced by left coronary ligation at 30 days post-surgery and (b) in rats with pressure-related cardiac hypertrophy induced by aortic banding at several time points (0.5, 1 and 4 h, and 1, 4, 7 and 28days) after surgery. Levels were compared with those in matched sham-operated controls. 3. The mRNA level of atrial natriuretic peptide was markedly increased (8-10-fold) in the left ventricle of animals with post-infarction heart failure. In contrast, there was only a modest (40940) increase in the level of adrenomedullin mRNA. In rats with pressure-induced cardiac hypertrophy the ventricular level of atrial natriuretic peptide mRNA was again markedly increased (maximum 10-fold). The increase was first noticeable at 24 h post-banding and persisted until 28 days. In contrast, there was no change in adrenomedullin mRNA level compared with sham-operated rats at any time point. 4. Despite having similar systemic effects, the expression of adrenomedullin and atrial natriuretic peptide in the left ventricle is differently regulated.
INTRODUCTION
Adrenomedullin (ADM) is a recently discovered 52-amino-acid vasoactive peptide which shares structural identity with calcitonin gene-related peptide and amylin. It was initially identified in phaeochromocytoma tissue [l] but subsequently shown to both circulate in plasma and be expressed in several tissues [2, 31 . Specific binding sites for ADM are present in endothelial and vascular smooth muscle cells and in multiple tissue beds, and at least part of the effect of ADM is mediated through increased cellular production of cyclic AMP [2, 31. Systemically, ADM causes a combination of vasodilatation, natriuresis and diuresis [2, 31. These actions are very similar to those of atrial natriuretic peptide (ANP) and it has been proposed that there may be complementary or synergistic interactions between ADM and other natriuretic peptides in maintaining volume and blood pressure homoeostasis, especially in pathophysiological states marked by vasoconstriction and/or fluid overload [2, 31. Support for this comes from recent studies which show that, like ANP, plasma ADM level is increased in subjects with hypertension [4, 5] or cardiac failure [6, 71. However, in addition to systemic effects, the various vasodilatory peptides may also have specific paracrine and/or autocrine actions in tissues sites, which may at least partly explain why multiple peptides with apparently similar systemic activities exist.
ANP is normally expressed in cardiac atria [8] but expression in left ventricular myocytes is markedly increased in heart failure and in pressure-induced cardiac hypertrophy. This has been observed both in animal models as well as in human ventricles [9-131. In addition to contributing to the elevation of plasma ANP level seen in heart failure and hypertension, the increased ventricular ANP may play an important local role in mediating ventricular adaptation and maintaining ventricular function in the face of increased wall stress [8] . ADM is also expressed in the heart [14] , and recent studies by Jougasaki et al. [6, 151 have shown increased ventricular ADM immunostaining in failing human hearts obtained at cardiac transplantation and increased levels of ADM in blood draining the left ventricle in patients with heart failure, suggesting that ventricular-derived ADM may also play an important role in the systemic and local response to heart failure. However, whether ventricular ADM gene expression is indeed increased, as for ANP, in heart failure and cardiac hypertrophy is not yet known. In this study, we therefore examined ventricular ADM gene expression in well-described rat models of heart failure and pressure-induced cardiac hypertrophy and compared the expression patterns with those of ANP.
METHODS

Animal models
Post-infarction heart failure model. Left ventricular RNAs for this analysis were available from a previous study designed to investigate the effects of angiotensin-converting enzyme (ACE) inhibition on expression of components of the renin-angiotensin system in post-infarction heart failure [ 161. Briefly, myocardial infarction was induced in 20-week-old male Wistar rats (approx. 400g) by ligation of the left main coronary artery under general anaesthesia and positive pressure ventilation using the technique of Selye et al. [17] . In our hands this gives rise to large infarcts affecting about 35 +5% of the left ventricular wall [18] . Animals were given 0.1 g intraperitoneally of ampicillin preoperatively to prevent infection and 0.15 ml of buprenorphine (300 pg/ml) for 2 days post-operatively to reduce pain. Sham animals were operated on identically except for placement of the ligature. The animals were allowed to recover for 24 h and survivors [loo% (16/16) for sham-operated rats, 96% (23/24) for post-infarction rats] were then randomly assigned to either receive or not receive the ACE inhibitor, perindopril, 1.5 mg.day-' akg-' given in drinking water. Animals were housed singly for the duration of the experiments with controlled temperature, humidity and light periods, and had free access to food and water. Two days before killing at 30 days, blood pressure was measured in conscious rats using the tail cuff technique as described previously [ 191. Animals were killed by cervical dislocation. Tissues were then rapidly removed and individually frozen in liquid nitrogen and stored at -70°C pending RNA extraction. The lungs and right ventricles were weighed before freezing.
Pressure-induced cardiac hypertrophy model. Twelve-week-old male Wistar-Kyoto rats (approx. 250g) were used for these studies. Under general anaesthesia induced and maintained by inhaled halothane (1-3%), a 0.45-0.50 mm diameter titanium clip (Atrauclip, Rusch UK Ltd, High Wycombe, U.K.) was placed around the suprarenal aorta through a midline abdominal incision using specially adapted pliers as previously described [20] to compress the aorta at this site by >70%. Shamoperated rats underwent the same surgery without placement of the clip. Animals (n = 6 per group per time point) were studied at 0.5, 1 and 4 h and 1, 4, 7 and 28 days post procedure. At each time point the heart was rapidly removed after killing by cervical dislocation, the left ventricle separated, weighed and immediately frozen in liquid nitrogen and stored at -80°C pending RNA extraction.
All procedures for both protocols were carried out in accordance with our institutional guidelines. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985) .
RNA extraction and mRNA analysis
Total tissue RNA was extracted using the LiCI/ urea precipitation method [21] . For the animals in the heart failure study, ventricles were pooled from two to three animals at a time to obtain three separate mRNA preparations for each group. For the animals in the cardiac hypertrophy study, RNA was prepared individually from six animals per group at each time point and pooled later as required for analysis (see Results). RNA concentrations were determined by spectrophotometry at 260 nm, and before Northern blot analysis substantial degradation of RNA during extraction was excluded by running aliquots on agarose gels stained with ethidium bromide.
Northern blotting and hybridization were performed using standard protocols [22] . Briefly, 60 pg of RNA per sample were electrophoresed through 1.2% (wlv) agarose gels containing 2.2 mol/l formaldehyde and transferred to Hybond N membrane (Amersham Ltd, Aylesbury, U.K.) as recommended by the membrane manufacturer. Membranes were then probed in random order to determine mRNA levels for ADM, ANP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (loading control) using the probes described below. Both cDNA probes (20 ng per reaction) were radioactively labelled with deoxy-( x-32P)CTP by the randomprimer method [23] and had specific activities greater than 1 x 10' c.p.m./pg DNA. The GAPDH probe (50 ng) was end-labelled using terminal deoxynucleotide transferase [22] .
For all probes, prehybridization (4 h) and hybridization (14-16 h) were carried out at 45°C in a buffer containing 50% (v/v) formamide, 6 x SSPE [1.08 mol/l NaCl, 0.06 mol/l sodium phosphate (pH 7.7), 6 mmol/l sodium-EDTA], 5 x Denhardt's (0.1% BSA/O. 1 % Ficoll 400/0.1% polyvinylpyrrolidone), 0.5% (w/v) SDS, 6% (w/v) polyethylene glycol 6000 and denatured salmon sperm DNA (200 pglml). After hybridization membranes were washed to a stringency of 0.5 xSSPE and 0.1% SDS at 60°C. Autoradiography was carried out at -70°C using Kodak X-Omat AR film (Eastman Kodak, Liverpool, U.K.) and intensifying screens. Before reprobing a previous probe was stripped from the membranes by immersion for 90 min at 65°C in two changes of a solution containing 10 mmol/l Tris/HCl (pH 8), 1 mmol/l EDTA and 1 x Denhardt's. Molecular masses of the bands seen on the membranes were estimated from a concurrently run RNA molecular mass ladder (Life Technologies, Paisley, Scotland, U.K.). Intensities of autoradiographic signals were quantified by 2D densitometry scanning using an LKB Ultrascan 2222-010 XL Scanner (LKB-Produkter AB, Bromma, Sweden). All samples to be compared were run, hybridized and autoradiographed together.
Probes
For ADM, a cDNA probe derived by reverse transcription/polymerase chain reaction amplification of rat kidney RNA was used. Primers used for amplification were 5'-GTGGGAAGAGGGAAC-TACAAG-3' (upstream) and 5'-GGAACCAAAcAACCTTACACC-3' (downstream), corresponding to base pairs 122-142 and 1056-1036 respectively of the published rat ADM cDNA sequence [14] . The resulting 935 bp fragment was cloned into pBluescript plasmid (Stratagene Ltd., Cambridge, U.K.) and sequenced from both ends to confirm its derivation from ADM mRNA. As probe, a 326 bp BglIIDra I subfragment containing sequence between base pairs 657 and 982 of the ADM transcript was gel-isolated. For ANP, a 0.7 kb ANP cDNA [24] (kindly provided by the U.K. DNA Probe Bank, probe number 288) was used and for GAPDH, a 29mer complementary oligonucleotide [25] was used.
Statistical analysis
For the heart failure study, results for quantitative variables were first compared by analysis of variance of all groups. Where this proved significant, pair- wise, comparisons were carried out using Tukey's test for multiple comparisons. Interactions between the effects of myocardial infarction and ACE inhibitor treatment were examined by two-way analysis of variance. For the cardiac hypertrophy study, values at each time for clipped and corresponding sham rats were compared by paired t-test. Figure 1 shows the results of probing RNAs from several rat tissues with the ADM and ANP probes. With the ADM probe a specific mRNA of approx. 1.4 kb, consistent with the predicted size of the ADM transcript [ 141, was detected. The highest level of ADM mRNA was seen in the adrenal gland but there was also significant expression in other tissues, especially the left ventricle and kidney. In contrast, the ANP probe detected a transcript of approx. 0.9 kb (the predicted size for ANP mRNA) only in the left ventricle. The findings are consistent with previous studies of the distribution of ADM and ANP mRNAs in the rat [2, 14, 261 and indicate that under the conditions used, the two probes selectively hybridized and detected their respective mRNAs.
RESULTS
In the heart failure study all sham-operated rats survived to 30 days. Mortality was 42% (5/12) in animals with myocardial infarction and 9% (1/11) in animals with myocardial infarction treated with ACE inhibitor as previously reported [16] . Table 1 shows the characteristics of the four groups of rats at the time of killing. Consistent with the size of infarction (see Methods) and the presence of severe heart failure, the rats with myocardial infarction had a marked ( > 2.5-fold, P<O.OOOl) increase in lung and right ventricular weights and a fall in blood pressure compared with sham-operated rats. ACE inhibitor treatment caused a small but insignificant reduction in lung weight in animals with myocardial infarction and a further fall in blood pressure (Table   Figure 2 shows left ventricular ADM and ANP mRNA levels in the four groups of the heart failure 1). study. Although difficult to discern visually, the ADM mRNA level was modestly increased in the rats with myocardial infarction (compare groups B and D with A and C). This is more clearly seen in Figure 3a which show the results of the densitometric analysis. In both groups of rats with myocardial infarction there was a significant (Pc 0.05) increase of around 40% in the ADM/GAPDH mRNA ratio compared with the corresponding control group. In a two-way analysis of variance, the effect of myocardial infarction on ADM/GAPDH mRNA ratio was highly significant (P = 0.003) while that of ACE inhibitor treatment was of borderline significance (P=O.O47). In contrast to the finding with ADM expression there was a marked upregulation of ventricular ANP gene expression in animals with heart failure ( Figure 2 ). In animals with myocardial infarction (Group B) there was a 10.1-fold increase in ANP/GAPDH mRNA ratio compared with the corresponding controls (Group A), while in animals with myocardial infarction receiving ACE inhibitor treatment (Group D) there was an 8.7-fold increase compared with their controls (Group C) ( Figure  3b ). The precise values for the increase in ANP mRNA level in the myocardial infarction groups need to be interpreted with some caution, as given the extreme change seed, they are likely to have been influenced by the saturation characteristics of the autoradiographic film [22] . Nonetheless, the results clearly demonstrate a striking qualitative difference in the behaviour of ADM and ANP mRNA.
In a two-way analysis of variance, the effect of myocardial infarction on ANP/GAPDH mRNA ratio was highly significant (P < 0.0001) while that of ACE inhibitor treatment was not significant (P = 0.430). 9.9-, 5.6-and 5.0-fold at 24 h, 4 days, 7 days and 28 days respectively. In contrast, no change was seen in ventricular ADM mRNA levels at any stage in the evolution of the cardiac hypertrophy. At 4 h a slight increase in ADM and mRNA levels was seen in both clipped and sham-operated rats (Figure 5) , suggesting a nonspecific response to the procedure.
DISCUSSION
Since its identification 4 years ago, ADM has emerged as a potentially important vasoactive factor that may play a role in both normal cardiovascular homoeostasis as well as in pathophysiological states associated with volume overload or vasoconstriction [2, 31. Its widespread expression suggests that in addition to systemic effects it may have tissuespecific paracrine and/or autocrine actions. Despite rapid advances, the precise functions of ADM and how its expression is regulated in uivo remain to be fully understood. Furthermore, how its biological actions differ from those of other vasodilatory and natriuretic peptides such as ANP is an important unanswered question. In this study we compared left ventricular expression of ADM with that of ANP in experimental post-infarction cardiac failure and in pressure-induced cardiac hypertrophy. We show that both qualitatively and quantitatively, the behaviour of ventricular ADM expression differs from that of ANP in these two pathological states. Our finding of a marked induction in ventricular ANP expression in both models examined is consistent with previous reports [9, 101. Immunohistochemical studies indicate that the site of increased ANP expression is the ventricular myocyte [9, 12, 13, 271. In the case of myocardial infarction, expression is particularly augmented in the myocytes in the marginal region of the infarction [27]. The precise mechanisms responsible for the increased ANP expression remain to be defined but cellular signals arising from the increased wall stress that occurs in both conditions are believed to play an important role. Specifically, members of the jun gene family which are activated as part of the early gene response to mechanical stretch have been shown to increase ANP gene transcription through the activator protein-1 complex [28] . The induction of ANP expression is part of a selective change in ventricular gene expression to a pattern seen during fetal development [29] . As such, it may play an important local role in the hypertrophy and remodelling of the myocardium that occurs in cardiac failure and left ventricular hypertrophy. In addition, the increased ventricular ANP expression is a major contributor to the elevated plasma ANP seen in these conditions [12, 131.
Although ventricular ADM expression and peptide level is much lower than that in the adrenal, the level is comparable to that in several other tissues [2, 31 and the mRNA is readily detectable by Northern blotting (Figure 1) . Further, immunohistochemical studies have localized the ADM to the ventricular myocyte [6, 301. In this study we show that ventricular ADM expression can be specifically modulated. Taken together these data suggest a functional role for ventricular ADM.
The totally different pattern of regulation of ADM expression compared with that of ANP is noteworthy for several reasons. The absence of increased expression in rats developing pressureinduced cardiac hypertrophy suggests that, unlike for ANP, mechanical wall stress is not an important regulator of cardiac ADM expression. In turn, the lack of change in ventricular ADM expression in the setting of marked ventricular growth and remodelling suggests that it is not involved in the cardiac adaptive response, at least to pressure overload.
In contrast to the animals with left ventricular hypertrophy, the left ventricles of animals with postinfarction heart failure showed a significant increase in ADM mRNA level. Although the increase was modest and much lower than that seen with ANP mRNA, it was consistent across two separate groups of rats (totalling 15 animals) with myocardial infarction (Figure 3a) , suggesting that this was a true effect. Our findings are also consistent with those of Jougasaki et al. [6, 151 , who found both an increased ADM immunoreactivity in failing human ventricles obtained at transplantation as well as a step-up in plasma ADM between aorta and the anterior interventricular vein (which drains the left ventricle) in subjects with congestive heart failure, suggesting net production of ADM by the failing ventricle. Quantitatively, there is also similarity between their findings and ours. The step-up they found in ADM level between aorta and anterior interventricular vein was only about 25% compared with a more than 200% step-up in ANP level [15] . Thus taken altogether, the data strongly point to increased expression, synthesis and secretion of ADM by the failing ventricle, but of a different magnitude to that seen for ANP.
The mechanism responsible for the enhanced expression of ADM in the failing ventricle remains to be identified. The absence of increased expression in response to pressure overload (see above) suggests that increased wall stress is not directly involved. The effect appears to be tissue-specific as in the same animals we did not see any change in ADM mRNA levels in the kidney or adrenal (results not shown). The increased expression may be a response to volume overload, although in a recent study Ishimitsu et al. [31] found no change in circulating ADM level by either acute or chronic salt loading in both normotensive and hypertensive subjects. Alternatively, the increased ADM expression may be a response to other hormones/factors that are activated in heart failure. An increasing number of such molecules that induce ADM production are being identified [3] . Specifically, Romppanen et al. [32] recently reported a 1.6-fold increase in left ventricular ADM mRNA in rats infused for 2 h with arginine8-vasopressin (0.05 pgemin-kg-l, intravenously), and a 1.5-fold increase in rats treated for 2 weeks with angiotensin I1 (33.3 pg) . Interestingly, the effect was seen in normotensive animals (Sprague-Dawley rats) but blunted in hypertensive rats [spontaneously hypertensive rat, TGR (mREN-2)27]. Also, it needs to be emphasized that although the study of Jougasaki et al. [6] found increased ADM immunostaining in myocytes of their subjects with heart failure, the precise cells with increased ADM expression in our model and their location (i.e. whether in the myocardial infarction scar tissue or in the surrounding myocardium as in the case of ANP [27] ) remain to be determined.
The functional consequences of the increased ventricular ADM expression in heart failure similarly remain to be elucidated. Locally, the ADM could enhance myocardial contractility via increased generation of CAMP [2, 31, although in an isolated perfused heart preparation no major changes in cardiac output, oxygen consumption, coronary flow or heart rate were seen [33] . Systemically, the natriuretic and vasorelaxing actions of ADM secreted from the ventricle could play a compensatory role in trying to optimize intravascular volume and cardiac filling pressures in the face of ventricular dysfunction. Plasma ADM concentration is 3-4-fold increased in subjects with cardiac failure [6, 71. The precise contribution of ventricular-derived ADM to this increase remains to be determined, but given the greater natriuretic potency of ADM compared with ANP [15] even a small increase may make a substantial impact.
Detailed investigation of the effect of ACE inhibitor on ADM expression was not a primary aim of our studies (see Methods). However, in the heart failure study there was a trend towards lower ventricular ADM mRNA level, of borderline significance, in animals treated with perindopril (Groups C and D, Figure 3a) . Since angiotensin I1 has been reported to induce ADM production in cultured vascular smooth muscle cells [3] and in the left ventricle in vivo [32] , the reduction in ADM mRNA may reflect an effect of ACE inhibition on angiotensin I1 generation. Alternatively, for animals in Group D, the decrease in ADM mRNA (as well as that of ANP mRNA) paralleled the modest decrease in lung and right ventricular weights (Table 1) and thus may simply reflect an improvement in cardiac dysfunction brought about by the ACE inhibitor. Certainly there is substantial evidence that ventricular production of ANP in cardiac failure correlates well with the extent of ventricular dysfunction [34] , and plasma ADM level also shows a correlation with clinical and haemodynamic parameters of left ventricular dysfunction [15] . In our study, the limited number of samples, the single time-point of study as well as the marked and uniform severity of the induced heart failure, precluded analysis of any relationship between the development and degree of cardiac failure and extent of induction of ventricular ADM expression. Likewise, although our data suggest that ACE inhibitors may modulate ventricular ADM expression either directly or through an effect on cardiac function, this requires further investigation.
In summary, we observed different regulation of left ventricular ADM and ANP gene expression in post-infarction cardiac failure and pressure-induced cardiac hypertrophy. In both cases ANP expression was markedly induced. In contrast, A D M expression was unchanged in cardiac hypertrophy and only modestly induced in cardiac failure. The findings suggest distinct roles for these two vasodilatory and natriuretic peptides in cardiovascular homoeostasis and pathophysiology.
